{"nctId":"NCT02690714","briefTitle":"A Study of Prometic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia","startDateStruct":{"date":"2016-05-04","type":"ACTUAL"},"conditions":["Hypoplasminogenemia","Congenital Plasminogen Deficiency"],"count":15,"armGroups":[{"label":"6.6 mg/kg Plasminogen (Human) Intravenous","type":"EXPERIMENTAL","interventionNames":["Biological: Plasminogen (Human) intravenous"]}],"interventions":[{"name":"Plasminogen (Human) intravenous","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject is a male or female between the ages of 2 and 80 years (inclusive), is able to provide informed consent or assent, and agrees to use contraceptive methods during the study (unless documented as biologically or surgically sterile or has not reached reproductive age).\n* Subject has documented history of hypoplasminogenemia and has plasminogen activity level â‰¤ 45%.\n* Subject had a documented history of lesions and symptoms consistent with a diagnosis of congenital plasminogen deficiency.\n* Subject has documented vaccination to hepatitis A virus (HAV) and hepatitis B virus (HBV), or has received the first dose of HAV and HBV vaccine prior to the first dose of IMP and is scheduled to receive the second vaccine dose.\n\nExclusion Criteria:\n\n* Subject has uncontrolled hypertension; clinical or laboratory evidence of an intercurrent infection; a malignancy within 3 years, except for basal or squamous cell skin cancer; a psychiatric disorder; chronic or acute clinically significant inter-current illness; or evidence of renal and hepatic dysfunction.\n* Subject is pregnant or lactating\n* Subject has a history of anaphylactic reactions to blood or blood products that may interfere with participation in study in the opinion of the investigator.\n* Subject is a previous organ transplant recipient; has received exogenous plasminogen within 2 weeks of the screening; has a history of anaphylactic reactions to blood or blood products; or has received another IRB-approved interventional clinical trial of a drug, biologic, or device within 30 days before the first dose of the IMP.","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"80 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Clinical Success in Number and Size of Lesions as Measured by Photographic or Other Imaging Modality Depending on the Organ System Affected or Change in Affected Organ Functionality at 48 Weeks.","description":"Overall clinical success was defined as 50% of participants with visible or other measurable lesions achieving at least a 50% improvement in lesion number/size or functionality impact from baseline. Visible lesions were defined as lesions that could be imaged and analyzed with digital photography. Non-visible lesions were defined as lesions whose dimensions could have been assessed by medical imaging studies (eg, computed tomography, magnetic resonance imaging, ultrasound, etc) or functional assessments (eg, spirometry, audiogram, oximetry, etc).Visible lesions that had both a length and width as measured by the 1mm scale, were referred to as \"measurable lesions\", and visible lesions that were too small to measure by the 1mm scale (length and/or width could not have been measured) were referred to as \"non-measurable lesions\".","paramType":"COUNT_OF_UNITS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null}]},{"measurements":[{"groupId":"OG000","value":"10","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]},{"type":"PRIMARY","title":"Number and Percentage of Particpants Who Achieved the Target Plasminogen Activity Trough Levels for at Least 3 Measurements in 12 Weeks During Segment 2","description":"Plasminogen activity is a measurement of functional plasminogen levels and is therefore the most accurate and specific method to quantify active Plasminogen (Human) Intravenous concentration in participants' plasma. Primary endpoint success was defined as at least 80% of evaluable participants (ie, 8 or more) achieving the target trough levels for at least 3 measurements in 12 weeks. The target trough level was defined as an increase in plasminogen activity level of at least an absolute 10% (10 U/dL) from the participant's individual baseline level.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Clinical Success in Number and Size of Lesions as Measured by Photographic or Other Imaging Modality Depending on the Organ System Affected or Change in Affected Organ Functionality at 12 Weeks","description":"Overall clinical success was defined as 50% of participants with visible or other measurable lesions achieving at least a 50% improvement in lesion number/size or functionality impact from baseline. Visible lesions were defined as lesions that could be imaged and analyzed with digital photography. Non-visible lesions were defined as lesions whose dimensions could have been assessed by medical imaging studies (eg, computed tomography, magnetic resonance imaging, ultrasound, etc) or functional assessments (eg, spirometry, audiogram, oximetry, etc).Visible lesions that had both a length and width as measured by the 1mm scale, were referred to as \"measurable lesions\", and visible lesions that were too small to measure by the 1mm scale (length and/or width could not have been measured) were referred to as \"non-measurable lesions\".","paramType":"COUNT_OF_UNITS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impression-Global Improvement (CGI-I) Scores at Week 12","description":"CGI-I scores are measured at 12 and 48 weeks after study drug treatment. The CGI-I Scale is a single, clinician completed scale designed to capture the clinician's impression of the participant's disease improvement over time.\n\nFor this scale, clinicians were asked to consider their experience in this population and rate the change relative to the participant's state at Baseline using a 7-point scale (1 = very much improved, 7 = very much worse).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"11","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impression-Global Improvement (CGI-I) Scores at Week 48","description":"CGI-I scores are measured at 12 and 48 weeks after study drug treatment. The CGI-I Scale is a single, clinician completed scale designed to capture the clinician's impression of the participant's disease improvement over time.\n\nFor this scale, clinicians were asked to consider their experience in this population and rate the change relative to the participant's state at Baseline using a 7-point scale (1 = very much improved, 7 = very much worse).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"13","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Improved Quality of Life (QOL) Score After 12 Weeks of Study Treatment","description":"Quality of life score (QOL) was measured at baseline and at 12 and 48 weeks after study drug treatment. For the QOL assessment, participants were asked to rate their overall QOL using an 11-point scale (0 = non-functioning, 10 = normal; The QOL scale was adapted from a scale developed by the American Chronic Pain Association.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Improved Quality of Life (QOL) Score After 48 Weeks of Study Treatment","description":"Quality of life score (QOL) was measured at baseline and at 12 and 48 weeks after study drug treatment. For the QOL assessment, participants were asked to rate their overall QOL using an 11-point scale (0 = non-functioning, 10 = normal; The QOL scale was adapted from a scale developed by the American Chronic Pain Association.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Plasminogen Activity Trough Levels Between Week 2 and Week 120","description":"Plasminogen activity trough levels were measured at Weeks 2, 4, 6, 8, 10, 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.1","spread":"15.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.9","spread":"14.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4","spread":"11.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.3","spread":"17.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.2","spread":"12.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.0","spread":"12.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.0","spread":"12.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.5","spread":"13.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.7","spread":"16.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.0","spread":"8.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.7","spread":"10.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.7","spread":"20.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.1","spread":"20.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.0","spread":"25.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.5","spread":"12.02"}]}]}]},{"type":"SECONDARY","title":"Plasminogen Antigen Trough Levels Between Week 2 and Week 120","description":"Plasminogen antigen trough levels were measured at Weeks 2, 4, 6, 8, 10, 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.550","spread":"3.0457"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.800","spread":"3.8813"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.268","spread":"3.3155"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.607","spread":"3.0046"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.460","spread":"7.1543"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.340","spread":"2.9342"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.913","spread":"2.2181"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.667","spread":"2.7336"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.973","spread":"3.1299"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.415","spread":"1.7578"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.083","spread":"2.2851"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.183","spread":"3.8129"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.656","spread":"4.2030"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.529","spread":"4.0852"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.550","spread":"6.2933"}]}]}]},{"type":"SECONDARY","title":"Half-life (t1/2) of Plasminogen Activity After First Dose and at Week 12","description":"t1/2 is time required for the plasma concentration of Plasminogen to decrease 50% in the final stage of its elimination","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":"11.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.2","spread":"6.22"}]}]}]},{"type":"SECONDARY","title":"AUClast of Plasminogen Activity After the First Dose and at Week 12","description":"AUCLast is the area under the plasma concentration-curve of Plasminogen from time 0 to the last measured concentration.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3063.6","spread":"778.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4656.0","spread":"1012.66"}]}]}]},{"type":"SECONDARY","title":"Cmax of Plasminogen Activity After First Dose and at Week 12","description":"Cmax is the maximum plasma concentration of Plasminogen","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":"23.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"125","spread":"23.3"}]}]}]},{"type":"SECONDARY","title":"Cl of Plasminogen Activity After First Dose and at Week 12","description":"Cl is the volume of plasma cleared of Plasminogen per unit time","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.44","spread":"0.460"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.92","spread":"0.257"}]}]}]},{"type":"SECONDARY","title":"AUCinf of Plasminogen Activity After First Dose and at Week 12","description":"AUCinf is the area under the plasma concentration-curve of Plasminogen from time 0 extrapolated to infinity","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3605.8","spread":"1023.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5731.8","spread":"1431.70"}]}]}]},{"type":"SECONDARY","title":"MRTlast for Plasminogen Activity After First Dose and at Week 12","description":"MRTLast is the mean residence time of Plasminogen from time 0 to the last measured concentration","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.6","spread":"3.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.5","spread":"1.60"}]}]}]},{"type":"SECONDARY","title":"Vss for Plasminogen Activity After First Dose and at Week 12","description":"Vss is the apparent volume of distribution at steady state of Plasminogen","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.3","spread":"11.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.3","spread":"10.36"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":15},"commonTop":["Nasopharyngitis","Headache","Oropharyngeal pain","Diarrhoea","Cough"]}}}